Traditional Chinese Medicine as Preventive Method for Osteoporosis Induced by Adjuvant Endocrine Therapy
To test the efficacy of two Traditional Chinese Medicine in preventing osteoporosis in patients receiving adjuvant endocrine therapy.
Breast Cancer|Osteoporosis
DRUG: Letrozole|DRUG: Zhongyaofufang|DRUG: Xianlinggubao
Change of Bone Mineral Density, The change of bone mineral density of the L2-L4 region of the spine and hip between pre- and post-endocrine therapy for one year, 1 year
Bone Frature Rate, the rate of bone fracture in patient receiving endocrine therapy, 1 year|Bone Metabolism, The change of bone metabolism assessed by the scale of serum bone alkaline phosphatase, serum C-telopeptide and urineN-telopeptide between pre- and post-endocrine therapy for one year, 1 year|Disease Free Survival, the rate of patients without disease, 1 year
Breast cancer is the most common malignant tumor in female wolrdwide. Results from clinical trials like ATAC trial have demonstrated the efficacy of AIs in postmenopausal breast cancer patients. Meanwhile it may cause a certain rate of osteoporosis in postmenopausal patients. The aim of this trial is to test the efficacy of two traditional Chinese medicine in preventing osteoporosis in patients receiving adjuvant endocrine therapy.